編者按：為滿足全球客戶日益增長的需求，藥明康德正積極加速全球產能布局與能力建設。未來兩年，公司計劃在美國、歐洲和亞洲持續擴建其一體化CRDMO平臺的原料藥及制劑產能。

其中，位于美國特拉華州的米德爾頓基地將于2026年底前投入運營，屆時將成為藥明康德在美國最大的運營基地。該基地預計于2026年第四季度啟動口服固體制劑生產，并于2027年第四季度開始無菌注射劑生產。

在歐洲，藥明康德正持續擴建瑞士庫威基地的制劑生產及包裝產能，以滿足不斷增長的商業化需求。該基地新增的PSD-4噴霧干燥車間預計于2026年第四季度投入運營。

位于亞洲的生產基地也在持續擴展布局。在中國泰興基地，兩個全新的小分子原料藥生產車間預計將在今年投入運營，而用于寡核苷酸、多肽和PMO生產的兩個新車間預計在2027年投產。此外，公司還計劃提前啟動常州新原料藥生產基地的建設。

新加坡基地也在加速建設中，同樣預計在2027年投入運營，進一步提升原料藥全球供應的靈活性，更好地支持小分子，以及寡核苷酸、多肽藥物及相關化學偶聯物（TIDES藥物）商業化生產需求。目前，泰興基地和新加坡基地仍有三個全新的TIDES車間建設正在推進中。

為支持上述擴產計劃，藥明康德預計今年的資本開支將達到65億元至75億元。通過持續優化全球運營網絡和一體化平臺能力建設，藥明康德始終致力于更好地滿足客戶需求，加速賦能全球醫藥創新，助力更多創新療法更快惠及患者。

日前，行業媒體Pharma Manufacturing的主編Greg Slabodkin采訪了公司聯席首席執行官陳民章博士，圍繞全球產能建設、新分子能力布局及未來發展戰略等話題展開深入交流。

以下為專訪內容精編，點擊“閱讀原文/Read More”即可訪問原文頁面。

Greg Slabodkin：全球宏觀政策等外部不確定因素，是否會影響藥明康德擴建全球產能的決策？

陳民章博士：我們全球產能擴張的核心驅動力始終只有一個：客戶需求。客戶需要更多產能，而我們正在全力建設以滿足這些需求。當前，尤其是在多肽及前沿小分子領域，客戶對我們服務的需求顯著增長，擴大產能規模是客戶與我們共同的期望。這才是驅動我們投資決策的根本原因。

當然，我們也密切關注全球宏觀政策的變化，但這并不是驅動公司增長戰略的核心因素。客戶選擇藥明康德，源于我們一體化CRDMO模式在質量、速度和效率方面的綜合優勢。我們持續擴大全球布局，是為了能夠更好地賦能客戶：無論客戶在哪里推進項目，我們都能滿足他們的需求。

Greg Slabodkin：藥明康德正在美國、歐洲和亞洲同步擴建產能，公司多地擴產戰略的目標是什么？

陳民章博士：我們的目標，是在符合全球標準的統一質量體系下，為客戶提供更多靈活選擇，助力構建更加安全、穩健的藥品供應鏈。客戶對我們在歐洲和美國的平臺能力在廣度與深度上都提出了更高要求，因此我們持續在這些地區加大投資。

例如，我們位于美國特拉華州米德爾頓的新基地，將首次在美國大規模開展制劑生產業務。同時，我們也正在持續擴建瑞士庫威基地能力，計劃于2026年新增噴霧干燥能力，后續還將增加無菌注射劑等相關能力。在亞洲，新加坡基地也將新增小分子、寡核苷酸、多肽及復雜偶聯物的原料藥生產能力，其一期項目預計于2027年開始投入運營。

Greg Slabodkin：在擴建原料藥和制劑產能方面，目前客戶需求增長主要集中在哪些特定領域？WuXi TIDES是否是公司增長最快的業務之一？

陳民章博士：目前需求來自多個治療領域，包括腫瘤、心血管及代謝疾病、傳染病、中樞神經系統疾病以及罕見病等。隨著產能的不斷提升，WuXi TIDES確實已成為我們在全球增長最快的業務之一，預計全年營收將實現約40%的同比增長。

WuXi TIDES能夠為客戶提供全方位的CRDMO能力，涵蓋復雜化學偶聯物、新型單體、連接子和配體的發現合成、工藝開發與任何規模的生產服務，實現從毫克級到商業化規模的全流程支持。

Greg Slabodkin：隨著藥物分子日益龐大且復雜，特別是寡核苷酸、多肽、靶向蛋白降解劑（TPD）和抗體偶聯藥物（ADC）等新分子的涌現，這是否直接驅動了藥明康德全球產能的擴張？支持這些新分子需要哪些核心能力？

陳民章博士：科學正在引領我們將目光投向結構更加復雜、治療更具靶向性的前沿分子。因此，寡核苷酸、多肽、TPD等新分子能力建設，是藥明康德重點投資方向之一。

在多肽領域，我們開發了多種一體化工藝路徑，通過將固相合成與液相合成相結合（SPPS–LPPS混合策略）來提升效率；在下游環節，我們根據具體多肽分子的特性和開發需求，靈活采用先進的純化及API分離技術，如切向流過濾（TFF）、連續流色譜及噴霧干燥，助力提高收率、工藝穩定性和可擴展性。

在寡核苷酸領域，我們同樣開發了多種創新工藝技術。比如固相與液相合成（SPOS和LPOS）、酶促合成等，進一步拓展合成復雜序列的效率；在下游純化與分離方面，我們采用薄膜蒸發（TFE）、連續流色譜等創新技術，簡化下游處理流程、減少工藝步驟。

與此同時，我們還在全球范圍內持續擴建相關產能。在中國泰興基地，兩個用于寡核苷酸、多肽和PMO生產的新車間正在建設中，預計于2027年投產；新加坡首個TIDES車間也將于2028年投入運營。

TPD和ADC領域也正在快速發展，但其面臨的核心挑戰之一，仍然是研發成果的可轉化性。我們經常會看到，一些在體外實驗中表現非常優異的化合物，進入細胞或動物體內之后，往往難以復制同樣的效果。這種情況在降解劑或ADC等復雜分子類型中更加明顯。與此同時，隨著檢測體系越來越復雜，如何高效解析大規模的數據，也逐漸成為新的挑戰。

針對這些問題，藥明康德的做法是盡可能在藥物發現早期，就把化學、生物學以及測試能力整合在一起。例如，構建更高質量的化合物庫，在關注活性的同時推進多參數優化，并加快化合物系列的篩選與迭代。

通過實時的數據整合，以及高效的一體化工作流程，我們可以幫助客戶在研發項目中，更早決定是繼續推進，還是及時終止。這在降低后期研發風險的同時，也能提升整體的研發效率。

我們在這些方面都進行了投資。例如，截至2025年底，我們的多肽固相合成反應釜（SPPS）總體積已提前完成超過10萬升目標，正在進一步擴建至13萬升，目前仍有三個全新的TIDES車間正在建設中。而寡核苷酸固相合成反應釜（SPOS）的總規模也已突破8摩爾。此外，截至2025年底，小分子原料藥反應釜也已經超過400萬升。

我們之所以進行這樣有針對性的產能與能力擴建，是基于深思熟慮的戰略決策，即前瞻性布局產能，從而確保客戶項目推進過程中不會面臨產能上的掣肘。

Greg Slabodkin：為什么藥明康德要“雙管齊下”，同時擴大小分子原料藥反應釜和多肽固相合成反應釜總體積？

陳民章博士：因為在這兩大領域，我們都看到了強勁的市場需求。根據弗若斯特沙利文（Frost & Sullivan）數據，全球研發管線正在快速擴張，無論是新分子類型還是活躍項目數量都在不斷增加。其中，小分子、多肽及寡核苷酸等合成類分子仍占據主導地位，在2024年的研發管線中占比達54.3%。

截至今年3月底，我們的小分子項目管線已達到3,550個，僅2026年第一季度就新增了328個。這一增長既得益于小分子口服GLP-1藥物的熱潮，也離不開其他強勁的項目管線的支撐。

值得注意的是，由于具備成本優勢、物流便利性以及患者依從性高等特點，小分子藥物依然是現代藥物的重要基石，每年FDA批準的新藥中，超過一半為小分子藥物。與此同時，PROTAC及分子膠等技術突破，使此前“不可成藥”的細胞內靶點成為可能，也正在進一步推動小分子領域需求增長。

藥明康德的CRDMO模式具備充分優勢，能夠把握這一不斷擴大的需求，并持續為客戶創造價值。隨著CRDMO項目不斷向后期臨床及商業化階段推進，客戶對生產規模的需求也會顯著提升。

這解釋了為何我們持續擴建常州和泰興基地的小分子原料藥產能。這兩個基地已于2025年3月以零缺陷順利通過FDA現場檢查。2026年第一季度，公司小分子D&M業務收入同比增長80.1%至69.3億元，也反映了項目管線持續向后期推進。

對于多肽領域而言，未來幾年同樣值得期待。多肽藥物正在深刻改變代謝疾病治療模式，更復雜的多肽偶聯技術和精準遞送方式，也正在不斷拓展精準醫療的邊界。

2026年第一季度，WuXi TIDES D&M客戶數量同比增長28%，項目數量同比增長59%，進一步體現了市場需求的持續增長，以及一體化CRDMO模式的價值受到認可。到2026年底，WuXi TIDES收入預計將實現約40%的同比增長，而這一增長與我們持續擴建產能密切相關。

Interview with Co-CEO Dr. Minzhang Chen: WuXi AppTec Expands Global Manufacturing Capacity as Customer Demand Accelerates

To meet growing customer demand globally, WuXi AppTec is increasing its capital expenditure at least 17% in 2026 to between RMB 6.5 billion and RMB 7.5 billion, as the company looks to add new drug substance and drug product manufacturing capacity over the next two years in Asia, Europe, and the United States.

Among its infrastructure investments, the contract research, development, and manufacturing organization (CRDMO) will begin operations later this year at a new 1.74 million-square-foot plant in Middletown, Delaware, which will be WuXi AppTec’s largest U.S. facility.

The Delaware drug product site, which will serve the CRDMO’s North American market, is scheduled to start operations in the fourth quarter of 2026 for oral solid dosage manufacturing — with plans to expand into sterile/injectable production in the fourth quarter of 2027.

In Europe, WuXi AppTec is boosting its drug product manufacturing and packaging capacity in Couvet, Switzerland — which the company contends is designed to support growing commercial demand, with a new PSD-4 spray dryer slated to become operational in the fourth quarter of 2026.

In China, two new small molecule active pharmaceutical ingredient (API) plants at WuXi AppTec’s Taixing site are planned to become operational this year, and two additional plants focused on oligonucleotides, peptides, and phosphorodiamidate morpholino oligomer (PMO) production are currently under construction and expected to be operational in 2027. WuXi AppTec also plans to build a new API production site in Changzhou ahead of schedule, according to the company.

A Singapore site, which is currently under construction, will be operational next year augmenting the CRDMO’s global API manufacturing network for both small molecules and oligonucleotides, peptides and related synthetic conjugates (TIDES drugs). Three new TIDES plants are under accelerated construction in Taixing and in Singapore.

In a Q&A with Pharma Manufacturing Editor-in-Chief Greg Slabodkin, WuXi AppTec Co-CEO Dr. Minzhang Chen discusses the company’s business strategy and planned investments.

How have tariffs and trade policy considerations influenced WuXi AppTec’s decision to expand global manufacturing capacity?

Chen:Our global manufacturing growth is driven by one dynamic: our customers need more capacity, and we are building it. Demand for our services — particularly in peptides and advanced small molecule modalities — has grown significantly, and our customers are asking us to scale with them. That’s what is driving our investment decisions. We monitor trade policy and tariffs closely, but they are not the engine of our growth strategy. Our customers choose WuXi AppTec because of the competitive advantages of our integrated CRDMO model — our quality, speed, and efficiency — and we are growing to ensure we can continue meeting their needs wherever they operate.

WuXi AppTec is expanding its manufacturing capacity in the U.S., Europe, and Asia. What is the goal of the company’s regionalization of manufacturing strategy?

Chen:The goal is to deliver a secure and robust drug product supply chain under a single quality system meeting global standards. Our customers are asking for more and broader capabilities in Europe and the U.S., so we have been making investments in those regions aim to meet this demand. Our Middletown, Delaware facility will bring our drug product manufacturing to the U.S. for the first time at this scale.

At the same time, we’re expanding the capabilities of our Couvet site in Switzerland, adding spray drying in 2026, followed by parenteral manufacturing and LNP capabilities. We’re growing in Asia, too: our Singapore site will add API manufacturing for small molecules, oligonucleotides, peptides and conjugates, with Phase I operations expected in 2027.

When it comes to adding new drug substance and drug product manufacturing capacity, are there certain areas of customer demand that are growing for WuXi AppTec? Is WuXi TIDES one of your fastest-growing businesses?

Chen:The demand is coming from a broad range of therapeutic areas including oncology, cardiovascular and metabolic diseases, infectious diseases, central nervous system disorders, and rare diseases. WuXi TIDES is one of our fastest-growing businesses globally, with full-year growth expected to be about 40% year-over-year as we continue to increase manufacturing capacity.

We can meet customers’ demands by offering a full range of CRDMO capabilities at any scale — from discovery synthesis and process development to the manufacturing of complex synthetic conjugates, novel monomers, linkers, and ligands. This is what WuXi TIDES offers, from milligram-scale synthesis all the way through to commercial supply.

Are the increasing size and complexity of drug molecules, especially new modalities like oligonucleotides, peptides, targeted protein degraders (TPDs), and antibody-drug conjugates (ADCs), driving WuXi AppTec’s global manufacturing expansion? What capabilities are needed to support these new modalities?

Chen:The science is moving toward molecules that are structurally more complex and therapeutically more targeted. For this reason, a key focus of WuXi AppTec’s investments is on increasing capabilities related to new modalities like oligonucleotides, peptides, and TPDs. For example, for peptides, we have developed integrated process approaches such as combining solid-phase and liquid-phase synthesis (SPPS–LPPS hybrid), enabling greater efficiency and scalability for longer and more complex sequences.

Downstream, we apply advanced purification and API isolation technologies such as tangential flow filtration, continuous flow chromatography and spray drying to help improve yield, process robustness, and scalability.

In oligonucleotides, we bring a similarly flexible and integrated approach. Innovations such as thin film evaporation (TFE), continuous flow chromatography help streamline downstream handling and reduce processing steps, while biocatalytic fragment ligation expands the toolkit for constructing more complex sequences. Meanwhile, we continue to expand manufacturing capacity and capabilities across the globe.

At our Taixing site in China, two additional plants dedicated to oligonucleotide, peptide and PMO production are currently under construction and scheduled to be operational in 2027, and the first TIDES plant in Singapore will be operational in 2028.

TPDs and ADCs are advancing rapidly as well, but translatability remains one of the key challenges. Compounds that perform well in vitro often fail in cellular or in vivo systems, especially with complex modalities like degraders or ADC payloads. At the same time, increasing assay complexity generates large datasets that are difficult to interpret efficiently. We address this by integrating chemistry, biology, and testing early in the discovery process. This includes designing higher-quality libraries, applying multi-parameter optimization beyond potency, and enabling rapid triage of chemical series.

By combining real-time data integration with iterative workflows, we can enable our customers to make earlier, more informed go or no-go decisions, thereby reducing downstream risk and improving overall efficiency. We have invested in all of these. For example, at the end of 2025, our total solid phase peptide synthesis (SPPS) reactor volume exceeded 100,000 liters, completed ahead of schedule. We are now expanding that to 130,000 liters, with three new production units under construction.

The total solid phase oligo synthesis (SPOS) reactor scale also exceeded 8 mol. Our total small molecule API reactor volume exceeded 4,000 kL at the end of 2025. This targeted expansion of our capacities and capabilities reflects a deliberate decision to build manufacturing infrastructure ahead of demand, so that customers do not face constraints as their programs advance.

Why is WuXi AppTec growing both total reactor volume of small molecule APIs and total reactor volume of solid phase peptide synthesizers?

Chen:Because there is proven demand for both segments. According to Frost & Sullivan, the global R&D pipeline has expanded significantly, both in the diversity of new modalities and the number of active programs. Synthetic molecules — specifically small molecules, peptides, and oligonucleotides — continue to dominate, representing 54.3% of the pipeline in 2024.

Our small molecule pipeline reached 3,550 molecules at the end of March this year. We added 328 new molecules in Q1 2026 alone. The growth is driven by both small molecule oral GLP-1 drugs, and other robust project pipelines. Notably, due to their economic affordability, logistical convenience, and high patient compliance, small molecules remain the cornerstone of modern medicines, accounting for over 50% drugs approved by FDA each year.

Recent scientific breakthroughs in technologies like PROTACs and molecular glues are further driving this demand by successfully targeting previously “undruggable” pathways inside the cell. WuXi AppTec’s CRDMO model is well positioned to capitalize on this expanding demand and deliver continued value to customers. As these programs in our CRDMO funnel advance through clinical stages into commercial manufacturing, the volume requirements increase substantially — which is why we have been expanding API reactor capacity in Changzhou and Taixing, both of which passed FDA on-site inspections in March 2025 with no observations. Q1 2026 small molecule D&M revenue rose 80.1% year over year to RMB 6.93 billion, reflecting that pipeline progression.

For peptides, the next few years will be very exciting for innovation. We are seeing peptide-based medicines are transforming treatment approaches in metabolic diseases, while increasingly sophisticated peptide conjugates and other targeted delivery technologies are expanding the possibilities for precision medicine.

In Q1 2026, the number of WuXi TIDES D&M customers increased 28% year-over-year, while that of molecules rose 59% year-over-year — reflecting both the increasing customer demand and the effectiveness of our CRDMO model. By the end of 2026, we expect TIDES revenue to grow by approximately 40% year-over-year. This capacity expansion and the revenue trajectory are directly connected.

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。